Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

Leukemia, Published online: 17 February 2024; doi:10.1038/s41375-024-02180-3Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

Source: Leukemia - February 17, 2024 Category: Hematology Authors: Marie S ébert Lucie Freiman Cendrine Chaffaut Agn ès Guerci Pierre Peterlin Sylvain Th épot Odile Beyne-Rauzy Sophie Park Thomas Cluzeau Fatiha Chermat Pierre Fenaux Claude Preudhomme Emmanuelle Clappier Sylvie Chevret Lionel Ad ès Nicolas Duployez Ma Source Type: research